These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 24852858)
21. Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. Barsukov YA; Gordeyev SS; Tkachev SI; Fedyanin MY; Perevoshikov AG Colorectal Dis; 2013 Sep; 15(9):1107-14. PubMed ID: 23668626 [TBL] [Abstract][Full Text] [Related]
22. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP; Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740 [TBL] [Abstract][Full Text] [Related]
23. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Ricardi U; Racca P; Franco P; Munoz F; Fanchini L; Rondi N; Dongiovanni V; Gabriele P; Cassoni P; Ciuffreda L; Morino M; Filippi AR; Aglietta M; Bertetto O Med Oncol; 2013; 30(2):581. PubMed ID: 23606239 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Wahba HA; El-Hadaad HA; Abd-Ellatif EA Med Oncol; 2012 Sep; 29(3):1693-8. PubMed ID: 21706368 [TBL] [Abstract][Full Text] [Related]
25. Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)". Di Genesio Pagliuca M; Turri L; Munoz F; Melano A; Bacigalupo A; Franzone P; Sciacero P; Tseroni V; Vitali ML; Delmastro E; Scolaro T; Marziano C; Orsatti M; Tessa M; Rossi A; Ballare A; Moro G; Grasso R; Krengli M Tumori; 2013; 99(1):61-7. PubMed ID: 23549002 [TBL] [Abstract][Full Text] [Related]
26. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484 [TBL] [Abstract][Full Text] [Related]
27. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837 [TBL] [Abstract][Full Text] [Related]
28. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Velenik V; Oblak I; Anderluh F Radiat Oncol; 2010 Sep; 5():88. PubMed ID: 20920276 [TBL] [Abstract][Full Text] [Related]
29. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. Salazar R; Navarro M; Losa F; Alonso V; Gallén M; Rivera F; Benavides M; Escudero P; González E; Massutí B; Gómez A; Majem M; Aranda E Clin Transl Oncol; 2012 Aug; 14(8):592-8. PubMed ID: 22855141 [TBL] [Abstract][Full Text] [Related]
32. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353 [TBL] [Abstract][Full Text] [Related]
33. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992 [TBL] [Abstract][Full Text] [Related]
34. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C; Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148 [TBL] [Abstract][Full Text] [Related]
35. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549 [No Abstract] [Full Text] [Related]
36. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207 [TBL] [Abstract][Full Text] [Related]
37. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M; Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228 [TBL] [Abstract][Full Text] [Related]